BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 32300895)

  • 1. Metabolic characterization of colorectal cancer cells harbouring different KRAS mutations in codon 12, 13, 61 and 146 using human SW48 isogenic cell lines.
    Varshavi D; Varshavi D; McCarthy N; Veselkov K; Keun HC; Everett JR
    Metabolomics; 2020 Apr; 16(4):51. PubMed ID: 32300895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabonomics study of the effects of single copy mutant KRAS in the presence or absence of WT allele using human HCT116 isogenic cell lines.
    Varshavi D; Varshavi D; McCarthy N; Veselkov K; Keun HC; Everett JR
    Metabolomics; 2021 Nov; 17(12):104. PubMed ID: 34822010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KRAS allel-specific activity of sunitinib in an isogenic disease model of colorectal cancer.
    Modest DP; Camaj P; Heinemann V; Schwarz B; Jung A; Laubender RP; Gamba S; Haertl C; Stintzing S; Primo S; Bruns CJ
    J Cancer Res Clin Oncol; 2013 Jun; 139(6):953-61. PubMed ID: 23455880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Higher metastatic efficiency of KRas G12V than KRas G13D in a colorectal cancer model.
    Alamo P; Gallardo A; Di Nicolantonio F; Pavón MA; Casanova I; Trias M; Mangues MA; Lopez-Pousa A; Villaverde A; Vázquez E; Bardelli A; Céspedes MV; Mangues R
    FASEB J; 2015 Feb; 29(2):464-76. PubMed ID: 25359494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of specific KRAS mutations in patients with colorectal peritoneal metastases.
    Tonello M; Baratti D; Sammartino P; Di Giorgio A; Robella M; Sassaroli C; Framarini M; Valle M; Macrì A; Graziosi L; Coccolini F; Lippolis PV; Gelmini R; Deraco M; Biacchi D; Aulicino M; Vaira M; De Franciscis S; D'Acapito F; Carboni F; Milone E; Donini A; Fugazzola P; Faviana P; Sorrentino L; Pizzolato E; Cenzi C; Del Bianco P; Sommariva A
    ESMO Open; 2024 Apr; 9(4):102976. PubMed ID: 38613907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Common and mutation specific phenotypes of KRAS and BRAF mutations in colorectal cancer cells revealed by integrative -omics analysis.
    Kundu S; Ali MA; Handin N; Conway LP; Rendo V; Artursson P; He L; Globisch D; Sjöblom T
    J Exp Clin Cancer Res; 2021 Jul; 40(1):225. PubMed ID: 34233735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Not All Kirsten Rat Sarcoma Viral Oncogene Homolog Mutations Predict Poor Survival in Patients With Unresectable Colorectal Liver Metastasis.
    Lin Z; Liu Y; Cai S; Yang C; Zhou L; Li W
    Technol Cancer Res Treat; 2021; 20():15330338211039131. PubMed ID: 34669528
    [No Abstract]   [Full Text] [Related]  

  • 8. BMP4 and PHLDA1 are plausible drug-targetable candidate genes for KRAS G12A-, G12D-, and G12V-driven colorectal cancer.
    Ohnami S; Maruyama K; Chen K; Takahashi Y; Hatakeyama K; Ohshima K; Shimoda Y; Sakai A; Kamada F; Nakatani S; Naruoka A; Ohnami S; Kusuhara M; Akiyama Y; Kagawa H; Shiomi A; Nagashima T; Urakami K; Yamaguchi K
    Mol Cell Biochem; 2021 Sep; 476(9):3469-3482. PubMed ID: 33982211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence and patterns of mutations in RAS/RAF/MEK/ERK/MAPK signaling pathway in colorectal cancer in North Africa.
    Jafari M; Laraqui A; Baba W; Benmokhtar S; Zaitouni SE; Ali AA; Bounaim A; Moujahid M; Tanz R; Mahfoud T; Sbitti Y; Annaz HE; Abi R; Tagajdid MR; Kochri SE; Lahlou IA; Hsaini HE; Belayachi L; Benjouad A; Ichou M; En-Nya A; Ennibi K
    BMC Cancer; 2022 Nov; 22(1):1142. PubMed ID: 36344948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association Between Specific Mutations in KRAS Codon 12 and Colorectal Liver Metastasis.
    Margonis GA; Kim Y; Spolverato G; Ejaz A; Gupta R; Cosgrove D; Anders R; Karagkounis G; Choti MA; Pawlik TM
    JAMA Surg; 2015 Aug; 150(8):722-9. PubMed ID: 26038887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential reprogramming of isogenic colorectal cancer cells by distinct activating KRAS mutations.
    Hammond DE; Mageean CJ; Rusilowicz EV; Wickenden JA; Clague MJ; Prior IA
    J Proteome Res; 2015 Mar; 14(3):1535-46. PubMed ID: 25599653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Correlation between KRAS mutations and clinicopathologic features in colorectal carcinomas].
    Gao J; Zhang J; Lu T; Li XY; Jia N; Liang ZY
    Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):595-8. PubMed ID: 23157826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A set of defined oncogenic mutation alleles seems to better predict the response to cetuximab in CRC patient-derived xenograft than KRAS 12/13 mutations.
    Chen D; Huang X; Cai J; Guo S; Qian W; Wery JP; Li QX
    Oncotarget; 2015 Dec; 6(38):40815-21. PubMed ID: 26512781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between perioperative oncological evaluation and recurrence using circulating tumor DNA with KRAS mutation in patients with colorectal cancer.
    Hayashi T; Yoshida Y; Yamada T; Tanaka K; Shimaoka H; Kajitani R; Munechika T; Nagano H; Matsumoto Y; Komono A; Sakamoto R; Aisu N; Yoshimatsu G; Yoshimura F; Hasegawa S
    Cancer Med; 2022 Aug; 11(16):3126-3135. PubMed ID: 35312176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In silico RNA-seq and experimental analyses reveal the differential expression and splicing of EPDR1 and ZNF518B genes in relation to KRAS mutations in colorectal cancer cells.
    Riffo-Campos ÁL; Castillo J; Vallet-Sánchez A; Ayala G; Cervantes A; López-Rodas G; Franco L
    Oncol Rep; 2016 Dec; 36(6):3627-3634. PubMed ID: 27805251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transcriptional and metabolic rewiring of colorectal cancer cells expressing the oncogenic KRAS
    Charitou T; Srihari S; Lynn MA; Jarboui MA; Fasterius E; Moldovan M; Shirasawa S; Tsunoda T; Ueffing M; Xie J; Xin J; Wang X; Proud CG; Boldt K; Al-Khalili Szigyarto C; Kolch W; Lynn DJ
    Br J Cancer; 2019 Jul; 121(1):37-50. PubMed ID: 31133691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Novel Multiplex Droplet Digital PCR Assay to Identify and Quantify KRAS Mutations in Clinical Specimens.
    Alcaide M; Cheung M; Bushell K; Arthur SE; Wong HL; Karasinska J; Renouf D; Schaeffer DF; McNamara S; Tertre MCD; Batist G; Kennecke HF; Karsan A; Morin RD
    J Mol Diagn; 2019 Mar; 21(2):214-227. PubMed ID: 30472330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutation-Specific and Common Phosphotyrosine Signatures of
    Tahir R; Renuse S; Udainiya S; Madugundu AK; Cutler JA; Nirujogi RS; Na CH; Xu Y; Wu X; Pandey A
    J Proteome Res; 2021 Jan; 20(1):670-683. PubMed ID: 32986951
    [No Abstract]   [Full Text] [Related]  

  • 19. Correlation between
    Aktar S; Islam F; Cheng T; Gamage SMK; Choudhury IN; Islam MS; Lu CT; Hamid FB; Ishida H; Abe I; Xie N; Gopalan V; Lam AK
    Genes (Basel); 2023 Sep; 14(9):. PubMed ID: 37761948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncogenic KRAS creates an aspartate metabolism signature in colorectal cancer cells.
    Doubleday PF; Fornelli L; Ntai I; Kelleher NL
    FEBS J; 2021 Dec; 288(23):6683-6699. PubMed ID: 34227245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.